GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sovateltide overview

Sovateltide is a synthetic analog of endothelin 1 acts as an anti-apoptotic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. Sovateltide is indicated for the treatment of patients with acute cerebral ischemic stroke.

Sovateltide (PMZ-1620, SPI-1620) is under development for the treatment of Alzheimer's disease, acute ischemic stroke (acute cerebral ischemic stroke), hypoxic-ischemic encephalopathy in neonates and spinal cord injury. The drug candidate is administered through intravenous route. The drug candidate targets endothelin B receptor. It was also under development for the treatment of non-small cell lung cancer, advanced biliary cancer, gallbladder cancer and carcinomas.

Pharmazz overview

Pharmazz, Inc.(Pharmazz) is an biopharmaceutical company with an approved product, promising drug pipeline focused on discovering, acquiring, developing, and commercializing therapeutics. It is headquartered in Willowbrook, Illinois, the US.

For a complete picture of Sovateltide’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.